Sabine Glaser

481 total citations
8 papers, 296 citations indexed

About

Sabine Glaser is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Genetics. According to data from OpenAlex, Sabine Glaser has authored 8 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 3 papers in Molecular Biology and 2 papers in Genetics. Recurrent topics in Sabine Glaser's work include Lung Cancer Treatments and Mutations (4 papers), Acute Myeloid Leukemia Research (2 papers) and Hemoglobinopathies and Related Disorders (2 papers). Sabine Glaser is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Acute Myeloid Leukemia Research (2 papers) and Hemoglobinopathies and Related Disorders (2 papers). Sabine Glaser collaborates with scholars based in Switzerland, Singapore and United States. Sabine Glaser's co-authors include Dae Ho Lee, Enriqueta Felip, Philippe Pultar, Mikhail Akimov, Myung‐Ju Ahn, Yi‐Long Wu, Xiaoqing Liu, Wu‐Chou Su, Li Zhang and Daniel S.W. Tan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Thoracic Oncology.

In The Last Decade

Sabine Glaser

8 papers receiving 289 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sabine Glaser Switzerland	5	211	137	104	52	50	8	296
Karin Berghoff Germany	8	123 0.6×	134 1.0×	120 1.2×	34 0.7×	69 1.4×	28	277
Gary Zeger United States	12	151 0.7×	156 1.1×	61 0.6×	55 1.1×	15 0.3×	19	315
R. K. Ramanathan United States	11	103 0.5×	292 2.1×	73 0.7×	35 0.7×	43 0.9×	32	370
Quanren Wang China	11	169 0.8×	314 2.3×	77 0.7×	103 2.0×	32 0.6×	25	440
Chen‐Yang Huang Taiwan	11	139 0.7×	180 1.3×	65 0.6×	23 0.4×	19 0.4×	37	356
J. Scheele Germany	7	146 0.7×	98 0.7×	53 0.5×	31 0.6×	53 1.1×	32	197
Pasquale Incoronato Italy	8	294 1.4×	311 2.3×	110 1.1×	39 0.8×	24 0.5×	17	397
Javier Rodríguez Spain	11	185 0.9×	247 1.8×	40 0.4×	83 1.6×	22 0.4×	20	351
Dario Nicolella Italy	9	158 0.7×	227 1.7×	108 1.0×	17 0.3×	33 0.7×	16	332
Samson Ghebremariam United States	7	217 1.0×	99 0.7×	65 0.6×	26 0.5×	52 1.0×	13	262

Countries citing papers authored by Sabine Glaser

Since Specialization

Citations

This map shows the geographic impact of Sabine Glaser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sabine Glaser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sabine Glaser more than expected).

Fields of papers citing papers by Sabine Glaser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sabine Glaser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sabine Glaser. The network helps show where Sabine Glaser may publish in the future.

Co-authorship network of co-authors of Sabine Glaser

This figure shows the co-authorship network connecting the top 25 collaborators of Sabine Glaser. A scholar is included among the top collaborators of Sabine Glaser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sabine Glaser. Sabine Glaser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Lindsay, Colin R., Rajwanth Veluswamy, Gilberto de Castro, et al.. (2023). A phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation.. Journal of Clinical Oncology. 41(16_suppl). TPS9158–TPS9158. 4 indexed citations

Wu, Yi‐Long, Li Zhang, Dong‐Wan Kim, et al.. (2021). Phase 1b/2 study of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated non-small cell lung cancer who received prior therapy: Final overall survival and safety.. Journal of Clinical Oncology. 39(15_suppl). 9048–9048. 2 indexed citations

Wu, Yi‐Long, Li Zhang, Dong‐Wan Kim, et al.. (2018). Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 36(31). 3101–3109. 244 indexed citations

Tan, Daniel Shao-Weng, Dae Ho Lee, Ross A. Soo, et al.. (2017). P3.02b-117 Phase Ib Results from a Study of Capmatinib (INC280) + EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1264–S1265. 6 indexed citations

Kohgo, Yutaka, Akio Urabe, Yurdanur Kılınç, et al.. (2015). Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias. Acta Haematologica. 134(4). 233–242. 11 indexed citations

Schmid, Mathias, Maria Domenica Cappellini, John B. Porter, et al.. (2009). Safety of Deferasirox (Exjade®) in Myelodysplastic Syndromes (MDS) and Non-MDS Patients with Transfusional Iron Overload: A Pooled Analysis Focusing On Renal Function.. Blood. 114(22). 1768–1768. 6 indexed citations

Glaser, Sabine, et al.. (2002). Calculating sample size bounds for logistic regression. Preventive Veterinary Medicine. 54(2). 105–111. 22 indexed citations

Glaser, Sabine. (1996). Application of Statistical Classification Methods to the Evaluation of In Vitro Tests. Alternatives to Laboratory Animals. 24(1). 49–62. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact